MANNKIND CORP
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
MNKD | NDAQ
Overview
Corporate Details
- ISIN(s):
- US56400P7069
- LEI:
- Country:
- United States of America
- Address:
- 1 CASPER STREET, 6810 DANBURY
- Website:
- https://mannkindcorp.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of innovative inhaled therapeutic products and devices. The company targets patients with endocrine and orphan lung diseases, as well as cardiometabolic conditions. Its flagship commercial product is Afrezza® (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin for adults with diabetes. MannKind also leverages its inhalation platform technology for partnered products, such as Tyvaso DPI® for pulmonary hypertension, and is advancing a pipeline of treatments for rare lung diseases, including nontuberculous mycobacterial (NTM) lung disease. The company has expanded its portfolio in cardiometabolic care through strategic acquisitions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all MANNKIND CORP filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for MANNKIND CORP
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for MANNKIND CORP via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
